Physician profile
Matthew Standridge
NPI 1841371697
$5,701.32
in general payments reported to CMS, 2019-2025
49 companies · $668 in 2025
The $668 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $934 · 2021: $890 · 2022: $311 · 2023: $406 · 2024: $793 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $564.44 | 2019-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.17 | 2019-2021 | |
| Organogenesis INC. | $349.20 | 2024-2025 | Apligraf, Affinity |
| Pfizer INC. | $346.36 | 2019-2024 | |
| Lilly USA, LLC | $340.11 | 2019-2022 | |
| Abbvie INC. | $270.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $261.04 | 2019-2023 | Spravato |
| Amgen INC. | $246.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $221.89 | 2019-2025 | Capvaxive, Vaxneuvance, Pifeltro |
| Novartis Pharmaceuticals Corporation | $221.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $220.88 | 2019-2024 | Arexvy |
| Smith+Nephew, INC. | $171.11 | 2024-2025 | Collagenase Santyl, Regranex |
| Kerecis Limited | $151.70 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Sanofi-Aventis U.S. LLC | $136.22 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Standridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.